<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:atom="http://www.w3.org/2005/Atom"  xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Ara in English - capital]]></title>
    <link><![CDATA[https://en.ara.cat/etiquetes/capital/]]></link>
    <description><![CDATA[Ara in English - capital]]></description>
    <language><![CDATA[es]]></language>
    <ttl>10</ttl>
    <atom:link href="http://en.ara.cat:443/rss-internal" rel="self" type="application/rss+xml"/>
    <item>
      <title><![CDATA[Ona Therapeutics captures 74.2 million euros to accelerate its cancer drugs]]></title>
      <link><![CDATA[https://en.ara.cat/economy/ona-therapeutics-captures-74-2-million-euros-to-develop-cancer-drugs_1_5758382.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/0898432a-b716-4ec8-9515-a823d1a33ea1_16-9-aspect-ratio_default_0.jpg" /></p><p>The<a href="https://www.ara.cat/economia/ona-therapeutics-irb-icrea-ronda-financament-30-milions-desenvolupar-medicament-metastasi-cancer_1_1131588.html" > Catalan biopharmaceutical Ona Therapeutics</a> has closed a Series B funding round of 74.2 million euros to continue developing its cancer treatments. The new capital injection has been co-led by Valencian investor Columbus Venture Partners and French manager Mérieux Equity Partners, in addition to the public Cofides and the family office Korys. Current partners also participated: Asabys Partners, Alta Life Sciences, Bpifrance, CDTI, FundPlus NV, and Ysios Capital. </p>]]></description>
      <dc:creator><![CDATA[Alberto Prieto]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/economy/ona-therapeutics-captures-74-2-million-euros-to-develop-cancer-drugs_1_5758382.html]]></guid>
      <pubDate><![CDATA[Thu, 04 Jun 2026 15:19:31 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/0898432a-b716-4ec8-9515-a823d1a33ea1_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The founder and chief executive officer of Ona Therapeutics, Valerie Vanhooren]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/0898432a-b716-4ec8-9515-a823d1a33ea1_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[The Catalan biopharmaceutical company closes a Series B round led by Columbus Venture Partners and Mérieux Equity Partners]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Why don't they go to Barcelona?]]></title>
      <link><![CDATA[https://en.ara.cat/opinion/why-don-t-they-go-to-barcelona_129_5472967.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/0575c9ab-5ba5-49a5-9fb3-c9bf6e138a1d_16-9-aspect-ratio_default_0.jpg" /></p><p>In many Catalan Assistance Centers (it's not clear what type) professionals (from numerous branches, but they're not trees) encounter quite a few cases that raise questions. Infection? Disease? Plague? Endemic? Mutation? Lobotomy? Yeah, why aren't more and more Catalans from outside the territory going to Barcelona?</p>]]></description>
      <dc:creator><![CDATA[Francesc Canosa]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/opinion/why-don-t-they-go-to-barcelona_129_5472967.html]]></guid>
      <pubDate><![CDATA[Sun, 17 Aug 2025 17:00:55 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/0575c9ab-5ba5-49a5-9fb3-c9bf6e138a1d_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[Barcelona in sight! BARCELONA]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/0575c9ab-5ba5-49a5-9fb3-c9bf6e138a1d_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[]]></subtitle>
    </item>
    <item>
      <title><![CDATA[Technofeudalism or technooptimism?]]></title>
      <link><![CDATA[https://en.ara.cat/opinion/technofeudalism-or-technooptimism_129_5456785.html]]></link>
      <description><![CDATA[<p><img src="https://static1.ara.cat/clip/1eba6352-ef00-476a-b34f-b3c24eab5217_16-9-aspect-ratio_default_0.jpg" /></p><p>Feeling dizzy in the face of technological developments is stupid. That's how the techno-optimist manifesto that went viral in 2023 makes you feel. A document promoted by Marc Andreessen, a serial entrepreneur known for being the father of the Netscape browser and Facebook. This manifesto uses an epic tone to present a series of statements based on the premise that technological progress is the only hope for humanity's great problems. To save humanity, it is necessary to let entrepreneurs do their work, in complete freedom, trusting in the proper functioning of free markets that have proven over time to adapt and evolve. This manifesto enthrones money as the driving force of economic growth that cannot be stopped. From the perspective of the manifesto, thinking about the social consequences, possible inequalities, or injustices, are unjustified fears that only make it more difficult. In fact, the document describes regulation, sustainability, social responsibility, and ethics as "zombie ideas," a remnant of communism.</p>]]></description>
      <dc:creator><![CDATA[Ester Oliveras]]></dc:creator>
      <guid isPermaLink="true"><![CDATA[https://en.ara.cat/opinion/technofeudalism-or-technooptimism_129_5456785.html]]></guid>
      <pubDate><![CDATA[Sun, 27 Jul 2025 19:01:10 +0000]]></pubDate>
      <media:content url="https://static1.ara.cat/clip/1eba6352-ef00-476a-b34f-b3c24eab5217_16-9-aspect-ratio_default_0.jpg" type="image/jpeg"/>
      <media:title><![CDATA[The EU approves new legislation to protect your personal data online.]]></media:title>
      <media:thumbnail url="https://static1.ara.cat/clip/1eba6352-ef00-476a-b34f-b3c24eab5217_16-9-aspect-ratio_default_0.jpg"/>
      <subtitle><![CDATA[]]></subtitle>
    </item>
  </channel>
</rss>
